• Patient-Reported Outcomes in Immuno-Oncology: An Educational Series

    Contains 10 Component(s)

    In this educational webinar series, hear from experts in the field discuss the basics of PROs, how PROs can be integrated into IO clinical care, and how PROs can be used in IO clinical trials.

  • The Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma

    Contains 5 Component(s), Includes Credits

    As the role of immunotherapies in treating patients with renal cell carcinoma (RCC) grows, keeping up with the pace of emerging data on combination therapy regimens, effective practices for monitoring and managing immune-related adverse events, and educating patients to empower informed decision-making can be challenging. This CME, CNE, and CPE-accredited educational program is designed to provide all members of the multidisciplinary care team knowledge and resources to successfully address practical issues and barriers faced in integration of immunotherapies into the treatment of renal cell carcinoma (RCC).

  • Case Studies in IO Webcast: A Closer Look at Care Delivery

    Contains 4 Component(s)

    Organized around four case studies, the discussion will focus on current clinical evidence for optimal selection of immunotherapy and use of combination therapy. Topics covered include monitoring for and managing irAEs, care coordination and communication with non-oncology specialists, and assessment of institution- or practice-specific gaps in IO integration. Shared decision-making, toxicity management, reimbursement, and survivorship will also be discussed. This activity is supported by an educational grant from Bristol Myers Squibb.

  • ASCO Direct™ Highlights - CAR T-Cell Therapy

    Contains 5 Component(s), Includes Credits

    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.